Developing infant nutrition products is a costly and time-consuming business. NIZO’s MicroColon model offers companies a solution to pre-screen ingredients, earlier in the development process. But could it be further optimised for the needs of infant nutrition companies?
Optimized model provides best results for testing ingredients of infant formula
NIZO’s MicroColon model offers companies a solution to pre-screen ingredients, earlier in the development process. This technology was initially set up with a common adult-like gut medium. To get a noticeably better result for pre-screening ingredients for infants, NIZO investigated this technology with a medium composition reflecting infants’ nutrient intake. NIZO successfully demonstrated that combining the MicroColon model with an infant-like gut medium, does provide the best results. This is good news for manufacturers of infant formula. The pre-screening of potential new microbiome modulators lets companies control their product development costs and timing.
Guus Kortman, Scientist and Senior Project Manager Microbiomics at NIZO, has been working on this expertise, to better represent the infant gut microbiota. In this video, Guus will explain how NIZO optimized the in vitro MicroColon model. The whole study has been summarized in a poster.